Menopause changes more than your periods. It shifts where your body stores fat — toward the abdomen — and chips away at muscle, alongside broader metabolic changes. That overlaps with exactly what a GLP-1 is working on, which is why hormone therapy and GLP-1s often come up in the same conversation. They're different tools, though, and it helps to be clear about which does what.
What HRT is (for women)
Menopausal hormone therapy (MHT, often just "HRT") replaces the estrogen that falls at menopause — usually paired with a progestogen if you still have a uterus, to protect the uterine lining. It comes as pills, skin patches, gels, and sprays. Its main job is treating menopausal symptoms, not weight.
Who benefits
HRT is generally considered for:
- Moderate-to-severe menopausal symptoms — hot flashes and night sweats (vasomotor symptoms), and genitourinary symptoms like vaginal dryness.
- Bone protection — it helps prevent the accelerated bone loss of menopause.
- The benefit–risk balance is most favorable when started near menopause (roughly under age 60 or within 10 years of your last period).
It's an individualized decision: the risks (including breast cancer and blood clots) depend on the type of hormones, how they're delivered, timing, and your personal and family history. This is a conversation with your clinician, not a one-size-fits-all.
The menopause–weight connection
After menopause, women tend to gain fat — especially visceral (deep abdominal) fat — and lose some muscle, with a less favorable metabolic profile. This is often when midlife women consider a GLP-1 for weight.
Where HRT and GLP-1s intersect
- HRT is associated with less visceral fat — but it is not a weight-loss treatment. In observational data, current HRT users had lower visceral fat and BMI than never-users, with the benefit fading after stopping — but HRT did not preserve muscle, and controlled data (e.g., in surgical menopause) found no body-composition benefit from HRT. So HRT can nudge fat , but it won't do a GLP-1's job.